The AT-hook of the Chromatin Architectural Transcription Factor High Mobility Group A1a Is Arginine-methylated by Protein Arginine Methyltransferase 6*

Riccardo Sgarra 1,2, Jae Ho Lee 3, Michel A. Tessari 1, Sandro Altamura 1, Barbara Spolaore 4, Vincenzo Giancotti 1, Mark T. Bedford 1, and Guidalberto Manfioletti 1,2

From the 1 Dipartimento di Biochimica, Biofisica e Chimica delle Macromolecole, University of Trieste, 34127 Trieste, Italy, 2 Science Park-Research Division, M. D. Anderson Cancer Center, The University of Texas Smithville, Texas, 78957, and 3 CRIBI Biotechnology Centre, University of Padua, 35131 Padua, Italy

The HMGA1a protein belongs to the high mobility group A (HMGA) family of architectural nuclear factors, a group of proteins that plays an important role in chromatin dynamics. HMGA proteins are multifunctional factors that associate both with DNA and nuclear proteins that have been involved in several nuclear processes, such as transcriptional regulation, viral integration, DNA repair, RNA processing, and chromatin remodeling. The activity of HMGA proteins is finely modulated by a variety of post-translational modifications. Arginine methylation was recently demonstrated to occur on HMGA1a protein, and it correlates with the apoptotic process and neoplastic progression. Methyltransferases responsible for these modifications are unknown. Here we show that the protein arginine methyltransferase PRMT6 specifically methylates HMGA1a protein both in vitro and in vivo. By mass spectrometry, the sites of methylation were unambiguously mapped to Arg57 and Arg59, two residues which are embedded in the second AT-hook, a region critical for both protein-DNA and protein-protein interactions and whose modification may cause profound alterations in the HMGA network. The in vivo association of HMGA and PRMT6 place this yet functionally uncharacterized methyltransferase in the well-established functional context of the chromatin structure organization.

HMGA1a belongs, together with its isoform HMGA1b, to the highly related protein HMGA2, to the high mobility group A (HMGA) family of non-histone chromosomal proteins (1, 2). HMGA family members are considered proto-oncogenes and, when overexpressed in cell line models, are able to transform cells or increase their malignancy. In addition, transgenic mice overexpressing HMGA develop different tumors (3–5).

HMGA proteins contain about 100 amino acid residues and have three DNA-binding domains called AT-hooks that mediate their ability to interact with the narrow minor groove of AT-rich DNA sequences (6). By binding to DNA and/or transcription factors, HMGA proteins can organize the assembly of nucleoprotein-DNA transcriptional complexes (called enhanceosomes) at the level of enhancers or promoters activating or repressing transcription of a large number of mammalian genes. For this reason, they are referred to as architectural transcription factors (6, 7). In addition to transcriptional regulation, HMGA proteins are involved in other nuclear processes, such as viral integration, RNA processing, DNA repair, and chromatin structural organization and remodeling, indicating HMGA as highly connected nodes in the chromatin protein network (3, 6, 8).

HMGA proteins are subjected to a variety of post-translational modifications (PTMs) that modulate their multi-interacting property with both DNA and proteins (9–15). HMGA1a and HMGA1b are constitutively phosphorylated by casein kinase 2 at the two or three serine residues of the C-terminal end (16). Cell cycle-dependent phosphorylation by p34/cdc2 kinase has been detected on Thr23 and Thr27 (numbers refer to human HMGA1a residues, flanking the second AT-hook and shown to cause a strong decrease in the DNA-binding affinity (17, 18). Likewise p34/cdc2, phosphorylation by protein kinase c on Thr25, Ser41, and Ser63 caused a significant reduction of DNA-binding affinity (13). Acetylation of Lys64 and Lys70 are critical for the stability of the enhanceosome assembled on the IFN-β gene (19, 20). In particular, acetylation of Lys24 by p300 CBP-associated factor (PACAF)/GCN5 results in the stabilization, whereas that of Lys64 by p300/CBP (CREB-binding protein) causes destabilization of the enhanceosome. Methylation is the most recent HMGA PTM reported (9–14). Arg25 within the first AT-hook of HMGA1a has been found methylated (monomethylated) in tumor cell lines, reaching in some samples up to 50% of total HMGA1a protein content. Methylation on this residue is modulated during the apoptotic process reaching highest levels at later stages, with the formation of apoptotic bodies (14). More recently, dimethylation on the same Arg25 residue has been reported by another group (21). An extensive study on both HMGA1a and HMGA1b proteins reported a high level of PTMs, and in particular, dimethylation of arginine and lysine residues was increased in breast cancer cells with higher metastatic potential (9, 10). Altogether, these data lead authors to suggest the existence of a PTM “code” for HMGA proteins similar to that reported for histones (10, 11). Although the kinases and acetyltransferases that are able to modify HMGA proteins have been identified, enzymes responsible for arginine and lysine residues are just starting to be discovered (22).

Protein (lysine and arginine) methylation is an emerging type of PTM that has added a new dimension to the signal transduction field (23, 24).

* This work was supported by grants from Associazione Italiana per la Ricerca sul Cancro, Milano, Italy, Ministero dell’Università e della Ricerca (Programmi di Ricerca di Rilevante Interesse Nazionale 2004), Università di Trieste, Italy (to G. M. and V. G.) and from Welch Foundation Grant G-1495 (to M. T. B.). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked “advertisement” in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

1 These authors contributed equally to this work.

2 To whom correspondence should be addressed: Dipartimento di Biochimica, Biofisica e Chimica delle Macromolecole, Università di Trieste, Via L. Giorgieri 1, 34127 Trieste, Italy. Tel.: 39-040-5583675; Fax: 39-040-5583694; E-mail manfiole@units.it.

3 The abbreviations used are: HMGA, high mobility group A; PRMT, protein arginine methyltransferase; PTM, post-translational modification; IFN-β, interferon β; CREB, cAMP-response element-binding protein; HIV, human immunodeficiency virus; HA, hemagglutinin; GFP, green fluorescent protein; GST, glutathione S-transferase; NPM, nucleophosmin; PABP1, poly(A)-binding protein 1; LC-MS, liquid chromatography-mass spectrometry; MS/MS, tandem mass spectrometry; HEK, human embryonic kidney; [3H]AdoMet, [3H]-labeled S-adenosyl-l-methionine; GAR, glycine arginine-rich.

© 2006 by The American Society for Biochemistry and Molecular Biology, Inc. Printed in the U.S.A.
At variance from histones, where the prevalent modification is lysine methylation (25), in HMGA proteins, arginine methylation seems particularly relevant (9, 11). Arginine methylation has been implicated in signal transduction, RNA metabolism, transcriptional regulation, and DNA repair (23, 24). Arginine residues are methylated by protein arginine methyltransferases (PRMTs). To date, two distinct PRMT activities have been found in mammalian cells; both types catalyze the formation of $\omega-N^\delta$-dimethyl arginine as an intermediate. Type I PRMT activity is defined by the formation of asymmetric $\omega-N^\delta,N^\epsilon$-dimethylarginine residues, whereas type II activity is defined by the formation of symmetric $\omega-N^\epsilon,N^\epsilon$-dimethylarginine residues. Currently, known type I enzymes include PRMT1, PRMT3, coactivator-associated arginine methyltransferase 1 (CARM1)/PRMT4, PRMT6, and PRMT8 (24). No activity has been demonstrated for PRMT2 (26, 27). The only type II PRMTs identified to date are the Janus kinase-binding protein JBP1/PRMT5 (28) and PRMT7 (29, 30).

In this manuscript, we have reported the identification of PRMT6 as a protein methyltransferase able to efficiently methylate in vitro and in vivo HMGA1a. PRMT6 has been recently identified as a type I PRMT enzyme with an exclusive nuclear localization (31). PRMT6 in vitro cellular substrates are unknown. In fact, if we exclude its autodemethylation activity, the only substrate identified so far is the viral Tat human immunodeficiency virus (HIV) protein (32). Tat-modified Arg residues have not been identified; thus its substrate specificity remains unknown. We report that PRMT6 methylates HMGA1a at the level of Arg57 and Arg59, not been identified; thus its substrate specificity remains unknown. We

**EXPERIMENTAL PROCEDURES**

**Plasmids**—Plasmids pARHMGA1a, pARHMGA1a-(1–80), pARHMGA1a-(1–52), pARHMGA1a-(35–107), pARHMGA1a-(46–107) expressing the wild-type and deletion mutants of human HMGA1a proteins were generated by PCR using the human HMGA1a cDNA as the template. The primers used for expression vector construction were as follows: A5–1, 5′-GAG AGA TAT ACA TAT GAG TGA GTC GAG CT-3′; A5–35, 5′-GCC AGC AGC ATA TGG GTA GTC CCG GGA CA; A5–46, 5′-TGG TAG GGC ATA TGA AGG AGC CCA GGC A-3′; A3–107, 5′-GCC AGC AGC ATA TGA AGG AGC CCA GGC A-3′; A3–80, 5′-GCC GCC GGC ATC CTT ATC ACT GCT CCT CCT C-3′; A3–80, 5′-GCC GCC GGC ATC CTT ATC ACT GCT CCT CCT C-3′; A3–80, 5′-GCC GCC GGC ATC CTT ATC ACT GCT CCT CCT C-3′; A3–80, 5′-GCC GCC GGC ATC CTT ATC ACT GCT CCT CCT C-3′; A3–80, 5′-GCC GCC GGC ATC CTT ATC ACT GCT CCT CCT C-3′; A3–80, 5′-GCC GCC GGC ATC CTT ATC ACT GCT CCT CCT C-3′; and A3–52, 5′-GCC GCC GGC ATC CTT ATC ACT GCT CCT CCT C-3′. The PCR products for deletion constructs at the C terminus were obtained using primer A5–1 in combination with the different A3 primers, whereas products for deletion constructs at the N terminus were obtained using A5–35 and A5–46 in combination with A3–107. The PCR products were cloned between the Ndel and BamHI sites of the bacterial expression vector pAR3038 under the bacteriophage T7 promoter. The resulting clones were verified by sequencing. Plasmids pARHMGA1aR52A, pARHMGA1aR57A, pARHMGA1aR59A, pARHMGA1aR57A,R59A were obtained using the QuickChange site-directed mutagenesis kit by Stratagene. The mutagenesis was performed via standard Stratagene protocol using as template the pARHMGA1a plasmid, except for pARHMGA1aR57A,R59A in which the template used was pARHMGA1aR59A, and using the following primers: R5759A (forward), 5′-CAC CTA AGA GAC CTT CGG GCG CAC CAA AGG-3′; R5759A (reverse), 5′-CCT TTG GTG GGC CCG CAG GTC TCT TAG GTG-3′; R575A (forward), 5′-CAC CTA AGA GAC CTT CGG GCG CAC CAA AGG-3′; R575A (reverse), 5′-CCT TTG GTG GGC CCG CAG GTC TCT TAG GTG-3′; R57A (forward), 5′-CCT TTG GTG GGC CCG CAG GTC TCT TAG GTG-3′; R59A (forward), 5′-GAG ACC TCG GGG CGC ACC AAA GAG AGG C-3′; R59A (reverse), 5′-GCT TCC CTG TGG TGC GCC GAG AGG TCT C-3′; R25A (forward), 5′-AGA AGC GGG GCC GCA GGC CCG C-3′; R25A (reverse), 5′-GCC GCC TGG CCG CCC GCT CCT-3′. Plasmids pcDNA3HA-PRMT6 and pcDNA3HA-PRMT1, expressing proteins in-frame with the hemagglutinin (HA) epitope, were obtained by cloning the open reading frames of PRMT6-GFP and PRMT1-GFP (31) into the BamHI/EcoRI sites and the EcoRI site of the pcDNA3HA vector, respectively. Plasmid pcDNA3HA-HMGA1a was obtained via subcloning using BamHI/EcoRI restriction sites from pcDNA1-HMGA1a (a gift of Dr. Thanos, Alexander Fleming Biomedical Sciences Research Cener, Vari, Greece), whereas the vector pcDNA3HA-nucleosomin (NPM) was obtained via PCR from the PINCO-HA-NPM retroviral vector (a gift of Dr. Pellicci European Institute of Oncology, Milan, Italy) using the following primers including the BamHI/NotI sites: NPM (forward), 5′-GCC AGG GAT CCA TGG AAG ATT CGA T-3′ and NPM (reverse), 5′-TTA AAG CGG CCG CTT AAA GAG ACT TCC C-3′ in the corresponding sites of pcDNA3HA. The plasmids pGEX6P1-PABP1 and pGEX2T-GAR, expressing the poly(A)-binding protein 1 (PABP1) and a protein arginine methyltransferase substate composed of the first 148 amino acids (glycine arginine-rich domain) of the human fibrillarin protein (both in fusion with the glutathione S-transferase (GST)) have been described previously (33, 34).

**Recombinant Protein Expression and Purification**—Recombinant HMGA proteins were expressed, extracted, purified, and analyzed by mass spectrometry as previously described (35). HMGA1a-(45–75) was a degradation product obtained during the preparation of HMGA1a-(45–106). GST fusion proteins were produced and purified as already described (31).

**Mass Spectrometry Analyses**—LC-MS analyses on PRMT6-methylated HMGA1a were carried out with an API 1 mass spectrometer (PerkinElmer SCIEX) as previously described (14). Mass values are reported as Da + 1. To identify the methylation sites, 10 μg of PRMT6-methylated HMGA1a were digested with 0.5 μg of Endoproteinase Lys-C sequencing grade (Roche Applied Science) for 18 h at 37 °C. HMGA1a fragments were analyzed by LC-MS as previously described (14) using a Waters Symmetry C18 3.5 μm, 1.0 × 150-mm column. All the LC-MS analyses performed with the API 1 mass spectrometer were carried out on the API 1 mass spectrometer allowing in this way to both record mass spectra and collect protein/peptide fractions for subsequent analyses. Tandem mass spectrometry (MS/MS) measurements were performed on a Q-TOF Micro mass spectrometer (Micromass, UK) equipped with a Z-spray nanoflow electrospray ionization interface. Mass spectra of the peptide digests of HMGA1a were acquired using the nano-electrospray source operating in positive ion mode. For the MS analyses, samples were dissolved in a 1:1 solution of acetonitrile:water containing 1% formic acid. Nano-electrospray ionization capillaries were prepared in-house from borosilicate glass tubing of 1 mm outer diameter and 0.78 mm inner diameter (Harvard Apparatus, Holliston, MA) using a Flaming/Brown P-800 PC micropipette puller (Sutter Instruments, Hercules, CA) and gold coated using an Edwards S-150B sputter coater (Edwards High Vacuum, West Sussex, UK). MS/MS analyses of the peptide (55–61) and its methylated forms were performed utilizing the same parameters of the MS instrument as above, using argon as the collision gas and a collision energy setting of 18 V. Instrument control and data acquisition and processing were achieved using the MassLynx software (Micromass,
HMGA1a in Vivo Methylation by PRMT6

UK). The relative ratio of the monomethylated peptides was calculated as the ratio between the relative peak intensity of the monomethylated peptide (1-Me) and the relative peak intensity of the unmethylated (0-Me) plus the monomethylated peptide (0-Me + 1-Me). Peptide relative intensity ratio = 1-Me/(0-Me + 1-Me).

**Blot Overlay**—Blot overlay experiments were performed essentially as previously described (8). Subconfluent HEK293 cells seeded on 100 mm-diameter Petri dishes were transfected with pcDNA3HA, pcDNA3HA-PRMT6, or pcDNA3HA-NPM by the conventional calcium phosphate procedure. Thirty-six hours later, the cells were washed with ice-cold phosphate-buffered saline and then harvested in 1 ml of ice-cold lysis buffer (50 mM Tris, pH 7.5, 150 mM NaCl, 0.1% Nonidet P-40) supplemented with protease inhibitors. Lysis was performed at 4 °C for 20 min. The lysates were then clarified by centrifugation and utilized as probes in the blot overlay experiments. Blot overlay membranes were incubated with an α-HA primary antibody (Santa Cruz Biotechnology) and bound primary antibodies visualized by enhanced chemiluminescence.

**Co-immunoprecipitation**—Subconfluent HEK293 cells were transfected with the indicated vector as described above and immunoprecipitation was performed as previously described (36).

**In Vitro Methylation**—In vitro methyltransferase assay, electrophoresis, and fluorography of methylation reactions were carried out as previously described (31).

**In Vivo Methylation**—Subconfluent HEK293 cells seeded on 100 mm-diameter Petri dishes were transfected with the indicated vectors as described above. Protein synthesis inhibition and in vivo methylation were carried out as previously described (33). Cells were washed with ice-cold phosphate-buffered saline and then harvested and lysed in 1 ml of ice-cold lysis buffer (50 mM Tris, pH 7.5, 150 mM NaCl, 0.1% Nonidet P-40, 1 mM phenylmethylsulfonyl fluoride, 5 mM NaF, 1 mM Na3VO4) supplemented with protease inhibitors (Sigma). Cell lysates were quantified using a standard Bradford method and 1 mg incubated with 8 mg of α-HA primary antibody (Sigma) prebound to 50 ml of protein A-Sepharose (Amersham Biosciences). The beads were then washed three times in ice-cold lysis buffer, and the bound proteins were solubilized by the addition of SDS sample buffer. Proteins were then separated by SDS-PAGE and transferred to nitrocellulose membranes. Western blot analyses were performed by standard procedures with an anti-HA primary antibody (Sigma) and enhanced chemiluminescence visualization. Radioactivity ([35S]methionine and methyl-[3H]) was visualized by fluorography; membranes were soaked in NAMP100 Amplify (Amersham Biosciences), air dried, and exposed to films at −80 °C for two months.

**RESULTS**

**HMGA1α Is a Substrate of PRMT6**—HMGA1α protein is methylated at the level of several arginine residues (9, 11). Because methyltransferases responsible for this post-translational modification were completely unknown, we decided to screen arginine methyltransferases for their ability to methylate HMGA1α. To this aim, pure recombinant HMGA1α protein, together with its isofrom HMGA1b and the highly related HMGA2, were incubated with the different recombinant PRMTs in the presence of 3H-labeled S-adenosyl-L-methionine ([3H]AdoMet) as a methyl donor. Methylated proteins were separated by SDS-PAGE and visualized by fluorography. All of the PRMTs (PRMT1, PRMT3, PRMT4, PRMT6, and PRMT7) that maintain their enzymatic activity as recombinant proteins were tested. Fig. 1 clearly shows that PRMT6 is the only arginine methyltransferase that is able to efficiently methylate HMGA1α and also the other HMGA proteins.

Interestingly, PRMT6 has an exclusive nuclear localization. Among the other methyltransferases tested, only PRMT1 and PRMT3 were able to weakly methylate HMGA2 (but not HMGA1α and HMGA1b). Recombinant GST-GAR was included as a positive control for PRMT1, PRMT3, and PRMT6, whereas GST-PABP1 is the positive control for PRMT4 (31). The newly described PRMT7 (29, 30) was tested at a later stage, but did not display any activity on HMGA proteins (data not shown).

**PRMT6 Methylates Arg Residues within the Second AT-hook of HMGA1α**—Because PRMTs are able to methylate short peptide sequences (33, 37, 38), to map the region of HMGA1α that is required for PRMT6 methylation, several HMGA1α deletion mutants were used. In addition, because methylation of Arg25 has been previously reported to occur at high levels in HMGA1α, point-mutated HMGA1αR25A was included. In vitro methylation reactions were performed as described above. Only the deletion of the second AT-hook region of HMGA1α (amino acids 52–79) is able to abolish methylation by PRMT6 (Fig. 2A, lane 6). All of the other deletion mutants that retain this region and also the point mutant R25A, which maps within the first AT-hook, are efficiently methylated by PRMT6 as the wild-type protein. As expected, PRMT1 did not display methylation activity on HMGA1α (Fig. 2A). The
same experiment was conducted also on HMGA1b deletion mutants with essentially the same result (data not shown).

**Arg57 and Arg59 Are Both Methylated by PRMT6**—To establish that PRMT6 can methylate the second AT-hook of HMGA1a (in the context of the full-length protein), we subjected HMGA1a to an in vitro methylation assay with recombinant PRMT6. This methylated HMGA1a was then analyzed by mass spectrometry to identify the modified arginine residue(s). Because this region contains four Arg residues, to precisely map the one(s) modified by PRMT6, an in vitro methylation time course of recombinant HMGA1a was carried out at 0, 4, and 32 h, respectively. HMGA1a methylation was confirmed by LC-MS analyses as shown by the appearance in the reconstructed mass spectra of mono-, di-, and trimethylated forms of HMGA1a (Fig. 3A). Both the 4- and the 32-h methylated HMGA1a were high pressure liquid chromatography-purified and endoproteinase Lys-C-digested. The LC-MS-digested map is reported in Fig. 3B. In Fig. 3C, the relative ratio of monomethylated peptides is reported. The 4-h experiment gave only one methylated peptide (55–61), whereas the 32-h experiment gave three methylated peptides (peptide-(23–30), (55–61), and (82–87)). The alignment of the sequence of these peptides (Fig. 3B, right) shows that they contain a similar arginine motif corresponding to the Arg-rich “core” domain of the three AT-hooks. These data indicate that, in agreement with the preceding in vitro radiolabeling experiments (Fig. 2), PRMT6 can methylate HMGA1a at multiple sites but that the preferred site maps to peptide-(55–61).

In Fig. 4A, a MS spectrum obtained with a Q-TOF mass spectrometer shows that the peptide-(55–61) (seen as triple-charged ion [M + 3H]3+) can be either unmethylated (m/z 289.52), monomethylated (294.19), or dimethylated (298.86). By tandem mass spectrometry, we obtained typical b and y ions for each of the three forms (Fig. 4B). On this peptide, there are three potential methylation sites: Arg55, Arg57, and Arg59. Because the b1 (m/z 157.11) and the b2 (m/z 254.15) ions are the same for all of the three forms (un-, mono-, and dimethylated) and no other signals are detected, we can conclude that Arg55 is never modified. Looking at the fragmentation ions obtained by the monomethylated form (m/z 294.19), Arg57 can be either unmethylated (b3 ion, m/z 205.62) or monomethylated (b3 ion, m/z 212.64). Because the precursor ion corresponds to the monomethylated peptide-(55–61), the implication is that when Arg57 is not modified, Arg59 must be methylated. This is confirmed from the y4 ions (m/z 457.26 and...
471.27), which indicate that Arg⁵⁹ can either be unmethylated or monomethylated. Fragmentation ions obtained from the dimethylated peptide (m/z 298.86) shows that Arg⁵⁷ is found unmethylated (b₃ ion, m/z 205.62) or dimethylated (b₃ ion, m/z 219.65) but never monomethylated. Again, because Arg⁵₅ is not modified, when Arg⁵⁷ is unmethylated, Arg⁵⁹ must be dimethylated. Indeed the y₄ ions (m/z 457.24 and 485.30) obtained from the fragmentation of the dimethylated 55–61 form show that Arg⁵⁹ can solely be unmethylated or dimethylated.

Therefore, MS/MS analysis indicates that both Arg⁵⁷ and Arg⁵⁹ can be methylated by PRMT6 but also that these two sites are mutually exclusive; once one of the two Arg is monomethylated, the addition of a second methyl group can only happen on the same residue. A scheme of the inferred methylation process is depicted in Fig. 4C.

MS/MS spectra of arginine-dimethylated peptides are often characterized by the presence of m/z signals arising from the loss of peculiar neutral fragments at the level of the methylated arginine (21). Depending on the symmetric or asymmetric nature of the dimethylation modification, it is possible to observe 70 or 45 Da neutral loss, respectively. The presence of a neutral loss of 45 Da, which corresponds to the loss of [NH(\text{CH₃})₂]dimethylamine from the dimethylated peptide-(55–61) during the MS/MS fragmentation, clearly indicates that PRMT6 catalyzes the formation of asymmetric ω-N²,N⁶-dimethylarginine (data not shown).

To confirm that Arg⁵⁷ and Arg⁵⁹ are substrates of PRMT6, single point mutants HMGA1aR⁵⁷A and HMGA1aR⁵⁹A and the double mutant HMGA1aR⁵⁷A,R⁵⁹A were generated substituting arginine with alanine and tested in in vitro methylation assays using PRMT6. Fig. 5 clearly shows that the single point mutants are both methylated less efficiently than the wild type, whereas in the double mutant, the methylation is drastically reduced, thus confirming the identity of the modified residues. The faint residual radioactivity incorporation observable in the HMGA1aR⁵⁷A,R⁵⁹A mutant is likely due to methylation at the level of the first and third AT-hook. Indeed, these domains, as demonstrated by the mass spectrometry data shown in Fig. 4C, are less efficiently methylated by PRMT6.

HMGA1a Associates with and Is in Vivo Methylated by PRMT6—
Certain PRMTs have been shown to interact with their substrates (39, 40). To demonstrate that HMGA1a can associate in vitro with PRMT6, a blot overlay was employed using wild-type HMGA1a along with several deletion mutants. As can be seen in Fig. 6A, HA-tagged PRMT6 expressed in HEK293 cells is able to associate in vitro with wild-type HMGA1a as well as with the other deletion mutants that retain the second AT-hook. Conversely, HMGA1a-(1–51), which has the second AT-hook removed, did not interact with PRMT6 (Fig. 6A, lane 5). HA-tagged NPM, a known interactor of HMGA1a (8), and the empty HA vector were used as positive and negative controls, respectively (Fig. 6A). The same region therefore that is methylated by PRMT6 is also responsible for the association with this enzyme.

To determine whether HMGA1a and PRMT6 interact in vivo, co-immunoprecipitation experiments were performed. HEK293 cells, which
express high levels of HMGA1a protein, were transfected with an HA-tagged PRMT6 expressing vector, cell lysates were immunoprecipitated with an α-HMG1 antibody, and subsequently the immunocomplexes were visualized with an α-HA antibody. As shown in Fig. 6C, PRMT6 associates with HMGA1a (lane 2). Complex formation was not detected in the absence of PRMT6 overexpression (lane 4). As controls, cell lysates were tested for the expression of HA-tagged PRMT6 (Fig. 6C, lanes 1 and 3, upper panel) and endogenous HMGA1 (lanes 1 and 3, lower panel). Taken together, these results clearly demonstrate that PRMT6 and HMGA1a physically associate both in vitro and in vivo, providing further support that PRMT6 can methylate HMGA1a.

To determine whether HMGA1a is methylated in vivo by PRMT6, HEK293 cells were transiently transfected with HA-tagged forms of PRMT6 and HMGA1a, and methylation was assessed by metabolic labeling with L-[methyl-3H]methionine as previously described (41). The in vivo methylation assay was performed in the presence of translation inhibitors to ensure that the labeling was not due to incorporation of methionine into newly synthesized proteins. HMGA1a was immunoprecipitated, resolved by SDS-PAGE, and visualized by fluorography. Fig. 7 shows that protein synthesis was inhibited (compare lanes 1 and 2 with lanes 4 and 5, lower panel) and that both HA-tagged HMGA1a and PRMT6 were efficiently and specifically immunoprecipitated (upper panel). As can be seen in Fig. 7, HMGA1a is specifically methylated by PRMT6; in fact, a band of the correct size is detectable only in PRMT6-transfected cells (Fig. 7, lane 11, lower panel) and not in cells transfected with the empty vector. The band below 20 kDa, detected in lanes 7 and 10, which appears methylated, very likely corresponds to histones.

**DISCUSSION**

In this report, we have identified HMGA1a as an in vivo cellular substrate of PRMT6 and mapped the methylated residues. PRMT6 is a novel arginine methyltransferase that was recently discovered by data base screening (31). It appears to be unique among the other type I PRMT and, in fact, is the only one to display automethylating abilities. A
PRMT6 orthologue has been identified in fish, where expression is seen predominantly in the brain (42). Similar to PRMT4, PRMT6 displays an exclusive nuclear localization (when expressed as GFP fusion proteins) (31). Recently, the HIV transactivator protein Tat was identified as a substrate of PRMT6. Tat methylation, occurring in the Arg-rich trans-activating domain, negatively regulates its transactivation activity and restricts HIV replication, thus demonstrating a role for PRMT6 in transcriptional regulation (32).

Here we found that PRMT6 methylates HMGA1a principally in the second AT-hook, at Arg57 and Arg59 and to a lesser extent in the third AT-hook (at Arg83 and Arg85, data not shown) and at a very low level in the first AT-hook. Interestingly, if we compare the sequence of the peptides found methylated in HMGA1a, we see that all of them share a core sequence constituted by Arg-Gly-Arg-Pro. The third AT-hook is more similar to the second, because there is a Pro and a Lys flanking the core sequence of both; therefore, the symmetrical sequence Pro-Arg-Gly-Arg-Pro seems to be the motif recognized in HMGA1a, even though addition flanking residues account for the preference for the second AT-hook. Of note, mass spectrometry data show that, within this sequence, only one Arg is found methylated (either mono- or dimethylated). Therefore, PRMT6 methylates Arg preceding a Gly independently on the orientation. This methylated sequence fits with the general consensus (F/G)GGRGG(G/F) suggested for the majority of type I PRMTs, with only the underlined Arg and Gly residues found in all methylated sites, and is most similar to the RGRG and PRG repeats methylated by PRMT1 (31). PRMT6 seems to be highly selective, having the ability to discriminate between subtle variations of the sequence surrounding the RG residues within HMGA1 AT-hook sequences. All three AT-hooks are highly conserved among the HMGA family, thus explaining why PRMT6 was able to methylate HMGA1b and the highly related HMGA2 in addition to HMGA1a. Furthermore, mass spectrometry data confirm the PRMT6 belonging to the type I
PRMT family, because it catalyzed the asymmetrical dimethylation of HMGA1a. Arg25, localized within the first AT-hook of HMGA1a, has been shown to be a major site of modification in tumor cells (11), but other Arg residues, in addition to those reported in this paper, have been found methylated in vivo (9, 10). In this study, we were unable to identify other PRMTs, except PRMT6, that modify HMGA1a protein. It is possible that a tissue-specific (or tumor-specific) factor could regulate the activity of a PRMT to facilitate HMGA1a methylation. Alternatively, there may be an HMGA code that requires an initiating PTM (such as phosphorylation or acetylation) that then facilitates subsequent arginine methylation.

All three AT-hooks of HMGA1a protein are involved in DNA interaction. All of them, in fact, are engaged at the same time when multiple stretches of AT bases are present in the DNA. In the absence of long AT run, it is the second AT-hook that has the highest affinity for DNA and that is engaged in DNA binding, either alone or in combination with the first or the second, depending on the DNA target (43, 44). NMR data obtained using a truncated HMGA1a form containing the second and third AT-hooks and a DNA target showed that the central Arg-Gly-Arg motif is engaged in interactions with both the DNA backbone and its bases establishing extensive hydrophobic and polar contacts (45). Here we report that the core of the second AT-hook can be subjected to PTM that can potentially modify its affinity for DNA.

---

**FIGURE 7. HMGA1a is in vivo methylated by PRMT6.** HEK293 cells were transiently transfected to express the indicated proteins (HA-PRMT6 and HA-HMGA1a), treated with protein synthesis inhibitors cycloheximide and chloramphenical (Cyc/Chl), and methylated proteins were labeled in vivo (using methyl-3H Met). Immunoprecipitations were carried out with α-HA antibody (α-HA) or with a pre-immune serum (PRE), and immunoprecipitated proteins were SDS-PAGE-analyzed, transferred onto nitrocellulose membranes, and visualized by Western blot using an α-HA antibody (right, upper side) and by fluorography (right, lower side) to detect 3H-labeled proteins. Total lysates (Input) were analyzed in parallel to verify the expression of the HA-tagged proteins. In the left part of the figure, a parallel control experiment is shown. HEK293 cells, expressing both HA-PRMT6 and HA-HMGA1a, were incubated with [35S]Met in the presence or absence of protein synthesis inhibitors to verify the protein synthesis inhibition. Bands detected in lanes 2, 3, 5, 6, 8, 9, 11, and 12 of the Western blot at ~26 kDa and just below 47 kDa correspond to the light and heavy chains, respectively, of the immunoglobulins used in the immunoprecipitation.

---

| Treatments and Transfections | Protein synthesis inhibition control | In vivo methylation |
|-----------------------------|-------------------------------------|---------------------|
| Methyl 3H Met               | -                                   | +                   |
| S Met                       | +                                   | +                   |
| Cyc/Chl                     | -                                   | -                   |
| pcDNA3HA-PRMT6              | +                                   | +                   |
| pcDNA3HA-HMGA1a             | +                                   | +                   |

---

**TABLE**

| Lanes | Western Blot | Fluorography |
|-------|--------------|--------------|
| 1     | 26 kDa       | 20 kDa       |
| 2     | 47 kDa       |              |
As mentioned, HMGA proteins not only interact with DNA but also with different nuclear proteins, including transcription factors (6, 8). The region where most of the interactions have been mapped includes the second AT-hook (6, 8); the possibility exists therefore that this modification can alter protein–protein interaction as well.

PTMs mapping within this region (phosphorylation by p34/cdc2 at Thr65 and Thr77 and acetylation by p300/CBP and PCAF/GCN5 at Lys46 and Lys70, respectively) have already been shown to alter HMGA1 functions (15, 17, 19, 44). A possibility exists that either methylation or phosphorylation per se could alter HMGA1a protein–DNA and/or protein–protein interaction or could participate in the interplay of PTM as has been shown for the methylation of histones. In the case of histone, PTMs are mechanistically linked, and different combinations of acetylation, phosphorylation, and monoubiquitination regulate chromatin structure and transcription by stimulating or inhibiting the binding of specific proteins (46).

PTMs can have a profound impact on HMGA1 function affecting its biological effect. Indeed, it has been shown that acetylation of Lys59 in HMGA1b (which corresponds to Lys70 of the isoform HMGA1a) was required for HMGA1b-induced apoptosis in normal rat thyroid cells (47). Arginine methylation in HMGA1a has been found to correlate with apoptosis and tumor progression (10, 11). It is therefore possible that this PTM can play a direct role in modulating the HMGA1a function in these two processes.

Arginine methylation is an emerging regulator of protein function; however, the practical consequences of this modification and its mode of regulation remain largely unknown. The finding, reported in this paper that the recently described PRMT6 associates with and in vivo methylates the HMGA1a protein, suggests a possible pathway for this PRMT, placing it in the highly connected network of chromatin proteins involved both in differentiation and neoplastic transformation.

REFERENCES

1. Johnson, K. R., Lehn, D. A., Elton, T. S., Barr, P. J., and Reeves, R. (1988) J. Biol. Chem. 263, 18338–18342
2. Manfioletti, G., Giancotti, V., Bandiera, A., Buratti, E., Sautiere, P., Cary, P., Crane-Robinson, C., Coles, B., and Goodwin, G. (1991) Nucleic Acids Res. 19, 6793–6797
3. Sgarra, R., Rustigia, A., Battista, S., Manfioletti, G., Rustighi, A., Poletto, D., Sciortino, M. T., Mastino, A., and Giancotti, V. (2001) J. Biol. Chem. 276, 11354–11361
4. Schwanbeck, R., Manfioletti, G., and Wiesniewski, J. R. (2000) J. Biol. Chem. 275, 1793–1801
5. Ferratti, P., Malorni, A., Marino, G., Pucci, P., Goodwin, G. H., Manfioletti, G., and Giancotti, V. (1992) J. Biol. Chem. 267, 22486–22492
6. Nissen, M. S., Langan, T. A., and Reeves, R. (1991) J. Biol. Chem. 266, 19945–19952
7. Reeves, R., Langan, T. A., and Nissen, M. S. (1991) Proc. Natl. Acad. Sci. U. S. A. 88, 1671–1675
8. Munshi, N., Agalioti, T., Lomvardas, S., Merika, M., Chen, G., and Thanos, D. (2001) Science 293, 1133–1136
9. Yie, J., Senger, K., and Thanos, D. (1999) Proc. Natl. Acad. Sci. U. S. A. 96, 13108–13113
10. Zou, Y., and Wang, Y. (2005) Biochemistry 44, 6293–6301
11. Miranda, T. B., Webb, K. J., Edberg, D. D., Reeves, R., and Clarke, S. (2005) Biochem. Biophys. Res. Commun. 336, 831–835
12. Lee, D. Y., Teysissier, C., Strahl, B. D., and Stallcup, M. R. (2005) Endocr. Rev. 26, 147–170
13. Bedford, M. T., and Richford, S. (2005) Mol. Cell 18, 263–272
14. Bannister, J. A., and Kouzarides, T. (2005) Nature 436, 1103–1106
15. Scott, H. S., Antonarakis, S. E., Lalioti, M. D., Rossier, C., Silver, P. A., and Henry, M. F. (1998) Genomics 38, 330–340
16. Zhang, X., and Cheng, X. (2003) Structure (Camb) 11, 509–520
17. Branscombe, T. L., Frankel, A., Lee, J. H., Cook, J. R., Yang, Z., Pestka, S., and Clarke, S. (2001) J. Biol. Chem. 276, 32971–32976
18. Lee, J. H., Cook, J. R., Yang, Z. H., Mirochnitchenko, O., Gunderson, S. I., Felix, A. M., Nerth, N., Hoffmann, R., and Pestka, S. (2005) J. Biol. Chem. 280, 3656–3664
19. Miranda, T. B., Miranda, M., Frankel, A., and Clarke, S. (2004) J. Biol. Chem. 279, 22902–22907
20. Frankel, A., Iyadav, N., Lee, J., Branscombe, T. L., Clarke, S., and Bedford, M. T. (2002) J. Biol. Chem. 277, 3537–3543
21. Boudlanger, M. C., Liang, C., Russel, R. S., Lin, R., Bedford, M. T., Wainberg, M. A., and Richford, S. (2005) J. Virol. 79, 124–131
22. Lee, J., and Bedford, M. T. (2002) EMBO Rep. 3, 268–273
23. Chang, C. Y., Gary, J. D., Clarke, S., and Herschman, H. R. (1998) J. Biol. Chem. 273, 16935–16945
24. Mantovani, F., Covaccuzsach, S., Rustigia, A., Sgarra, R., Heath, C., Goodwin, G. H., and Manfioletti, G. (1998) Nucleic Acids Res. 26, 1433–1439
25. Tesari, M. A., Gestinsa, M., Altamura, S., Sgarra, R., Rustigia, A., Salvagno, C., Caretti, G., Imbriano, C., Mantovani, R., Del Sal, C., Giancotti, V., and Manfioletti, G. (2003) Mol. Cell. Biol. 23, 9014–9116
26. Schurte, B. T., Koh, S. S., Chen, D., Bunick, G. J., Harp, J. M., Hanb, B. L., Hensch Edman, A., Mackay, D. R., Stallcup, M. R., and Aswald, D. W. (2001) Biochemistry 40, 5747–5756
27. Chom, T. R., Tung, J., Xu, Y., Guanacchi, C., Hersman, H. R., Pongor, S., and Aletta, J. M. (2003) J. Neurosci. Res. 67, 435–442
28. Swierzcz, R., Person, M. D., and Bedford, M. T. (2005) Biochem. J. 386, 85–91
29. Herrmann, F., Bossert, M., Schwander, A., Akgun, E., and Fackelmayer, F. O. (2004) J. Biol. Chem. 279, 48774–48779
30. Lee, J., Cheng, D., and Bedford, M. T. (2004) Methods Mol. Biol. 284, 195–208
31. Hung, C. M., and Li, C. (2004) Gene 340, 179–187
32. Maier, F. F., and Nathans, D. (1996) Proc. Natl. Acad. Sci. U. S. A. 93, 6716–6720
33. Yie, J., Merika, M., Munshi, N., Chen, G., and Thanos, D. (1999) EMBO J. 18, 3074–3089
34. Hult, J. R., Bewley, C. A., Nissen, M. S., Evans, J. N., Reeves, R., Gronenborn, A. M., and Clore, G. M. (1997) Nat. Struct. Biol. 4, 657–665
35. Petersen, C. L., and Laniel, M. A. (2004) Curr. Biol. 14, 546–551
36. Fedele, M., Pianetti, G., Merklen, M., Battista, S., Baldiassarre, G., Munshi, N., Dentice, M., Thanos, D., Santoro, M., Viglietto, G., and Fusco, A. (2001) Cancer Res. 61, 4583–4590